Condition: Pulmonary Disease, Chronic Obstructive · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, Chognqing, China | — |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | — |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | — |
| Guigang People's Hospital | Guigang, Guangxi, China | — |
| Zunyi Medical University Affiliated Hospital | Zunyi, Guizhou, China | — |
| Puyang Oilfield General Hospital | Puyang, Henan, China | — |
| Yichang Central People's Hospital | Yichang, Hubei, China | — |
| The People's Hospital of Liuyang | Changsha, Hunan, China | — |
| Xiangtan County People's Hospital | Xiangtan, Hunan, China | — |
| The Affiliated Hospital of Inner Mongolia Medical University | Hohhot, Inner Mongolia, China | — |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | — |
| Yixing People'S Hospital | Wuxi, Jiangsu, China | — |
+ 17 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.